Efgartigimod for nerve damage from Sjogren's disease
Treatments studied
Part of Brain & nervous system, Immune system & allergy, Pain clinical trials.
This study tests a new medicine called efgartigimod to see if it can help people with Sjogren's disease who have nerve damage (neuropathy). You may be able to join if your nerve symptoms started within the last 5 years and are getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with Sjogren's disease, and a blood test must show a certain antibody (anti-Ro/SS-A).
- You must have nerve damage from Sjogren's (like numbness, tingling, or weakness) that started within the last 5 years and has been getting worse in the past year.
- Your nerve symptoms must be at least moderately severe, as judged by a doctor's exam.
- You cannot have another condition (like rheumatoid arthritis or lupus) that could explain your symptoms.
- You cannot have had more than 3 steroid treatments (like prednisone) for asthma or COPD in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication called ONO-4915 for people with primary Sjögren's disease. It aims to see if the drug can reduce dryness and other symptoms.
This program provides early access to an investigational medication called efgartigimod for adults with CIDP who haven't responded well to usual treatments. The drug aims to reduce the immune attack on nerves and may help manage symptoms when other options fail.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This trial looks at people with Sjögren who may have small-fiber nerve problems that can cause pain, temperature-related nerve symptoms, or body-function nerve issues. It aims to understand how these nerve problems affect quality of life and medical needs, and compare them with people without neuropathy.
Hear when a new Sjogrens Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.